Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC.

Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11.

2.

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF; Gynecologic Oncology Group.

Gynecol Oncol. 2008 Jan;108(1):3-9. Epub 2007 Oct 18.

3.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D.

N Engl J Med. 2006 Dec 28;355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.

4.

Molecular and pathologic aspects of endometrial carcinogenesis.

Hecht JL, Mutter GL.

J Clin Oncol. 2006 Oct 10;24(29):4783-91. Review.

PMID:
17028294
5.

Expression of the epidermal growth factor system in endometrioid endometrial cancer.

Ejskjaer K, Sørensen BS, Poulsen SS, Forman A, Nexø E, Mogensen O.

Gynecol Oncol. 2007 Jan;104(1):158-67. Epub 2006 Sep 7.

PMID:
16962163
6.

Targeting tyrosine kinases in cancer: the second wave.

Baselga J.

Science. 2006 May 26;312(5777):1175-8.

PMID:
16728632
7.

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM.

J Clin Oncol. 2006 May 20;24(15):2376-85. Erratum in: J Clin Oncol. 2006 Jul 20;24(21):3515. Maxwell, Larry G [corrected to Maxwell, G Larry].

PMID:
16710036
8.

Racial disparities research: it's not just black and white.

Maxwell GL, Risinger JI.

Gynecol Oncol. 2006 May;101(2):194-7. No abstract available.

PMID:
16701108
9.

Rare uterine cancers.

Acharya S, Hensley ML, Montag AC, Fleming GF.

Lancet Oncol. 2005 Dec;6(12):961-71. Review. Erratum in: Lancet Oncol. 2006 Feb;7(2):105.

PMID:
16321764
10.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N.

N Engl J Med. 2005 Oct 20;353(16):1673-84.

11.

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.

Cancer. 2005 Oct 1;104(7):1391-7.

12.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Epub 2005 Mar 7. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
13.

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.

Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.

J Clin Oncol. 2004 Aug 1;22(15):3126-32.

PMID:
15284264
14.

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM.

J Clin Oncol. 2004 Aug 1;22(15):3080-90.

PMID:
15284258
15.

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.

Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH.

Gynecol Oncol. 2003 Dec;91(3):463-9. Review.

PMID:
14675663
16.

Uterine papillary serous carcinomas: the exigency for clinical trials.

Podratz KC, Mariani A.

Gynecol Oncol. 2003 Dec;91(3):461-2. No abstract available.

PMID:
14675662
17.

Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

Chan JK, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev SA, Berman ML.

Gynecol Oncol. 2003 Jul;90(1):181-5.

PMID:
12821361
18.
19.

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N.

J Clin Oncol. 2001 Oct 15;19(20):4048-53.

PMID:
11600606
20.

Treatment of uterine papillary serous carcinoma with paclitaxel.

Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM.

Gynecol Oncol. 2001 Jul;82(1):156-61.

PMID:
11426978

Supplemental Content

Support Center